Loading company
Aligos Therapeutics, Inc.
ALGS · Nasdaq · ·
Next earnings: November 5, 2026
$5.54+2.6%Sep 29 close
- 1M
- -19.8%
- 6M
- -15.5%
- 1Y
- -43.5%
- 5Y
- -98.6%
ALGS · Nasdaq · ·
Next earnings: November 5, 2026
$5.54+2.6%Sep 29 close
Aligos Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $965K | -100.00% |
| Profit | -$1.5M | -$15.9M | +90.52% |
| Profit per share | -$0.14 | -$1.53 | +90.85% |
| Free Cash Flow | -$22.4M | -$20.9M | -6.90% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aligos Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Aligos Therapeutics, Inc. has no earnings call transcript available.